The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition-Reference-Cited by-同舟云学术

The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition

Published:2022-03-26 Issue:7 Volume:42 Page:1503-1516
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Matthews David W.¹²^ORCID,Coleman Samantha³^ORCID,Razavi Homie³^ORCID,Izaret Jean‐Manuel¹²

Affiliation:

1. The Boston Consulting Group Boston Massachusetts USA

2. The Bruce Henderson Institute New York New York USA

3. The Center for Disease Analysis (CDA) Lafayette Colorado USA

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15245

Reference35 articles.

1. European Union Pharmaceutical Markets: A Case for Differential Pricing?

2. Outcomes‐based pharmaceutical contracts: an answer to high U.S. drug spending?;Seeley E;Commonw Fund,2017

3. Buying cures versus renting health: Financing health care with consumer loans

4. Payment by Capitation and the Quality of Care

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges for gene therapy in the financial sustainability of health systems: a scoping review;Orphanet Journal of Rare Diseases;2024-06-24

2. Revamping hepatitis C global eradication efforts: towards simplified and enhanced screening, prevention, and treatment;Translational Gastroenterology and Hepatology;2024-04

3. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update;The Lancet Gastroenterology & Hepatology;2024-04

4. Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank;American Heart Journal;2024-04

5. Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugs;International Journal of Drug Policy;2023-01